Dose adjustment of ciprofloxacin in renal failure: Reduce the dose or prolong the administration interval?

European Journal of Medical Research

Volumn 10, Issue 4, 2005, Pages 145-148

  Czock, David ^a   Rasche, F M ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Antimicrobials; Ciprofloxacin; Dose adjustment; Nephropharmacology; Pharmacodynamics; Pharmacokinetics; PK PD; Renal failure; Simulation

Indexed keywords

CIPROFLOXACIN;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; COMPUTER PROGRAM; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; ERADICATION THERAPY; ESCHERICHIA COLI; KIDNEY FAILURE; KIDNEY FUNCTION; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; SIMULATION;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KIDNEY FAILURE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

EID: 17844383262     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Aminimanizani A, Beringer P, Jelliffe R (2001) Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 40: 169-187
2. Bennett WM (1979) Drug prescribing in renal failure. Drugs 17: 111-123
3. de la Pena A, Grabe A, Rand KH, Rehak E, Gross J, Thyroff-Friesinger U, Muller M, Derendorf H (2004) PK-PD modeling of the effect of cefaclor on four different bacterial strains. Int J Antimicrob Agents 23: 218-225
4. Dettli L (1976) Drug dosage in renal disease. Clin Pharmacokinet 1: 126-134
5. Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC (1987) Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother 31: 860-864
6. Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2: 289-300
7. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37: 1073-1081
8. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL (2003) Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112: 275-285
9. Levy G (1994) Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 56: 356-358
10. Long CL, Raebel MA, Price DW, Magid DJ (2004) Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother 38: 853-858
11. Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31: 510-518
12. Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother 48: 2061-2068
13. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL (2002) Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 19: 355-358
14. Scaglione F, Mouton JW, Mattina R, Fraschini F (2003) Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother 47: 2749-2755